checkAd

     104  0 Kommentare New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856 Presented at Alzheimer's Conference - Seite 3

    New data strengthening the continued clinical development of NeuroRestore ACD856 presented at Alzheimer's conference

    Lesen Sie auch

    SOURCE: AlzeCure Pharma



    View source version on accesswire.com:
    https://www.accesswire.com/729420/New-Data-Strengthening-the-Continued ...


    The AlzeCure Pharma Stock at the time of publication of the news with a raise of +2,31 % to 0,355EUR on Frankfurt stock exchange (30. November 2022, 08:11 Uhr).

    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Accesswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856 Presented at Alzheimer's Conference - Seite 3 STOCKHOLM, SE / ACCESSWIRE / November 30, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the …